このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)

This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a relative with the same (or nearly the same) blood cell type as the transplant recipient. An investigational medication will be given prior to and after the transplant to help protect the transplanted kidney from attack by the body's immune system.

調査の概要

詳細な説明

Of the two currently available treatments for kidney failure, long-term dialysis and kidney transplantation, only kidney transplantation provides a potential cure. After a kidney transplant, the body's immune system recognizes the kidney as foreign and tries to attack and destroy it in a process called rejection. To avoid rejection, participants must take medications called immunosuppressants or anti-rejection drugs. It is believed that by transplanting bone marrow at the same time as a solid organ such as a kidney, a state of "mixed chimerism" (a mixing of the donor and recipient's immune system) can be achieved. Mixed chimerism may prevent rejection without the need for anti-rejection drugs.

Participants in this study will receive a simultaneous bone marrow and kidney transplant from the same living related donor in an attempt to establish mixed chimerism. Prior to transplantation, participants will undergo a "conditioning regimen" involving cyclophosphamide chemotherapy, radiation to the thymus gland, and four immunosuppressive medications: cyclosporine A, a man-made antibody known as rituximab to suppress B cells, a short course of steroids, and a T-cell depleting antibody known as MEDI-507. MEDI-507 is an investigational medication that has not been approved by the FDA. The primary goal of the study is to investigate the safety of the conditioning regimen and its ability to promote mixed chimerism so that the transplanted kidney is not destroyed. The study will also determine whether participants with mixed chimerism can eventually be safely removed from long-term immunosuppressive therapy following transplantation.

Participants will be assessed before and after transplantation and will be followed ≤36 months.

研究の種類

介入

入学 (実際)

5

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~55年 (大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • End-stage renal disease (ESRD) without prior sensitization (defined as Panel Reactive Antibody [PRA] greater than 20%) within the 60 days prior to transplant as measured by cytotoxicity assays, ELISA, and flow cytometry;
  • Undergoing a first or second transplant;
  • Receiving a transplant from a living related donor who is ABO (blood type) compatible and haploidentical (3, 4, or 5 antigen match by serologic typing);
  • Cardiac ejection fraction greater than 40%;
  • Forced expiratory volume (FEV1) greater than 50%;
  • Liver function tests, bilirubin, and coagulation studies less than 2 X normal;
  • White blood cells greater than 2000/mm^3; abd
  • Platelets greater than 100,000/mm^3

Exclusion Criteria:

  • Positive donor lymphocyte cross-match;
  • HIV-1 infected;
  • Positive hepatitis B surface antigen (HbsAg);
  • Hepatitis C virus infected;
  • History of cancer;
  • Prior dose-limiting radiation therapy;
  • Pregnant, breastfeeding, or planning pregnancy within the time frame of the study;
  • Enrolled in another investigational drug study within 30 days prior to study entry; or
  • Receiving maintenance immunosuppression within 3 months before the conditioning regimen begins

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Conditioning Regimen

Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.

Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.

Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
他の名前:
  • nonmyeloablative preparative regimen

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Graft Survival Twenty-Four Months Post Transplantation
時間枠:24 months (2 Years) Post Transplantation
Defined by kidney transplant survival at month 24 post transplantation with successful withdrawal of cyclosporine following transplantation, in the absence of maintenance immunosuppression.
24 months (2 Years) Post Transplantation

二次結果の測定

結果測定
メジャーの説明
時間枠
Participant Survival
時間枠:Up to thirty-six months (3 Years) Post Transplantation
During the three-year post-transplant follow-up period for enrolled participants.
Up to thirty-six months (3 Years) Post Transplantation
Graft Survival
時間枠:Up to thirty-six months (3 Years) Post Transplantation
During the three-year post-transplant follow-up period for enrolled participants.
Up to thirty-six months (3 Years) Post Transplantation
Change from Baseline in Renal Function Using Serum Creatinine
時間枠:Up to thirty-six months (3 Years) Post Transplantation
Changes in serum creatinine levels from baseline through post transplantation follow-up period.
Up to thirty-six months (3 Years) Post Transplantation
Number of Episodes of Acute or Chronic Graft Versus Host Disease (GVHD)
時間枠:From Week 1 through thirty-six months (3 Years) Post Transplantation
Evaluations for suspected GVHD, including biopsies as appropriate, during routine and/or for cause assessments.
From Week 1 through thirty-six months (3 Years) Post Transplantation
Number of Adverse Events
時間枠:Participant enrollment through <=thirty-six months (3 Years) Post Transplantation
As defined by protocol.
Participant enrollment through <=thirty-six months (3 Years) Post Transplantation

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:David H. Sachs, MD、Department of Medicine, Massachusetts General Hospital
  • 主任研究者:A. Benedict Cosimi, MD、Department of Medicine, Massachusetts General Hospital

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2003年6月1日

一次修了 (実際)

2009年1月1日

研究の完了 (実際)

2009年7月1日

試験登録日

最初に提出

2003年7月7日

QC基準を満たした最初の提出物

2003年7月7日

最初の投稿 (見積もり)

2003年7月8日

学習記録の更新

投稿された最後の更新 (実際)

2017年12月27日

QC基準を満たした最後の更新が送信されました

2017年12月22日

最終確認日

2017年12月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • DAIT ITN010ST
  • DAIT NKD03 (その他の識別子:Immune Tolerance Network)

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する